During the last decade, IWA Water Losses Task Force members have developed a systematic practical approach to the technical management of non-revenue water and its components, with (since 2002) increasing use of 95% confidence limits in these calculations. The current Water Losses Task Force has recently set itself an objective to develop a quick and practical method for calculating economic intervention (for active leakage control to locate unreported leaks and bursts), and short-run economic leakage level. This paper outlines a quick and practical method for assessing economic intervention frequency (and associated budgetary and volumetric parameters) for an active leakage control policy based on regular survey. Calculations are based on three key parameters: natural rate of rise of unreported leakage, marginal cost of water, and cost of intervention. It is hoped this will encourage Utilities that do not currently undertake active leakage control to adopt an ongoing basic active leakage control policy which can be simply demonstrated as being economic for their own situation.

Since its introduction in the early 2000s, robotic surgery has represented a significative innovation within a minimally invasive surgery approach. A variety of robotic platforms have been made available throughout the years, and the outcomes related to those platforms have been described in the literature for many types of surgeries. Medtronic’s HugoTM RAS system is one of the newest robotic generations launched, but because of its recent placing on the field, comprehensive clinical data are still lacking. The aim of the present state of the art is to address the current literature concerning the use of the HugoTM RAS robot in order to report its feasibility, safety and clinical applications in different surgical branches. Two reviewers independently conducted a search on the “PubMed” electronic database, using the keywords “Hugo” and “Hugo RAS”. After the initial screening of 35 results, a total of 15 articles concerning the Hugo RAS system were selected for the review, including both oncological and benign surgery. Patients’ demographic and baseline data were compared including, when available, docking system times, complications and oncological outcomes in the fields of urologic, gynecologic and general surgery. With reference to urological procedures, a total of 156 robot-assisted radical prostatectomies, 10 robot-assisted partial nephrectomies, and 5 robot-assisted adrenalectomies were performed, involving a total of 171 patients. The surgical branch in which the Hugo system found its major application was urology, which was followed by gynecology and general surgery. The Hugo RAS system by Medtronic represents an innovative and safe surgical platform, with excellent perspective for the future and different clinical applications in many surgical branches. More studies are needed to validate the safety and results from this new robotic platform.

No abstract

No abstract

No abstract